Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

PURPOSE: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free survival (DFS). Due to specific side effects, the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kähler, Katharina C., Hüning, S., Nashan, D., Meiss, F., Rafei-Shamsabadi, D. A., Rissmann, H., Colapietro, C., Livingstone, E., Maul, L. V., Heppt, M., Hassel, J. C., Gutzmer, R., Loquai, C., Heinzerling, L., Sachse, M. M., Bohne, A. S., Moysig, L., Peters, W., Rusch, J., Blome, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465664/
https://www.ncbi.nlm.nih.gov/pubmed/37405475
http://dx.doi.org/10.1007/s00432-023-05027-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465664/
https://www.ncbi.nlm.nih.gov/pubmed/37405475
http://dx.doi.org/10.1007/s00432-023-05027-z

Ejemplares similares